AKBA
AKBA
NASDAQ · Biotechnology

Akebia Therapeutics Inc

$0.91
-0.04 (-4.66%)
As of Aug 8, 10:25 PM ET ·
Financial Highlights (FY 2026)
Revenue
268.06M
Net Income
-6,070,381
Gross Margin
82.9%
Profit Margin
-2.3%
Rev Growth
-6.9%
D/E Ratio
5.94
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 82.9% 82.9% 34.7% 34.7%
Operating Margin 9.9% 9.0% -4.5% -4.8%
Profit Margin -2.3% -2.2% -5.9% -6.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 268.06M 287.87M 65.59M 81.13M
Gross Profit 222.25M 238.67M 22.75M 28.15M
Operating Income 26.67M 25.78M -2,955,557 -3,890,676
Net Income -6,070,381 -5,866,991 -3,878,355 -4,942,326
Gross Margin 82.9% 82.9% 34.7% 34.7%
Operating Margin 9.9% 9.0% -4.5% -4.8%
Profit Margin -2.3% -2.2% -5.9% -6.1%
Rev Growth -6.9% -6.9% +11.6% -8.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 113.17M 113.17M 21.85M 26.69M
Total Equity 19.07M 19.07M 127.43M 136.15M
D/E Ratio 5.94 5.94 0.17 0.20
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 26.67M 27.21M -4,128,349 -4,627,733
Free Cash Flow -1,979,346 -2,914,255